AstraZeneca’s Science Committee Chairman retires

FILE PHOTO: The logo of AstraZeneca is seen on a medication package at a pharmacy in London April 28, 2014. To match Insight CHINA-CANCER/BLACK MARKET REUTERS/Stefan Wermuth/File Photo

AstraZeneca’s Bruce Burlington will retire at the end of August 2017 as a Non-Executive Director and as a member of the Audit Committee, the Nomination and Governance Committee, and from his role as Chairman of the Science Committee, after seven years’ stay with the company. 

Leif Johansson, Chairman of AstraZeneca, praised Burlington’s contribution to the Board’s work over the years. “We have valued his insightful and frank participation as a Board member, and Chairman of the Science Committee during a period of innovation-led transformation at AstraZeneca. His diligence and commitment to the work of the Audit Committee and the Nomination and Governance Committee should also be acknowledged. On behalf of all Board members, we will miss Bruce as a colleague and send him our very best wishes for the future,” said Johansson.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.